12:00 AM
 | 
Aug 14, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BLP25: Began Phase IIb trial

Biomira Inc. (TSE:BRA; BIOM), Edmonton, Alberta
Product: BLP25
Business: Cancer
Therapeutic category: Immune stimulation
Target: T cells
Description: Liposomal synthetic 25-amino acid peptide...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >